Immune thrombocytopenia (ITP) is an autoimmune disease. Mesenchymal stem cells (MSCs) play important roles in the physiology and homeostasis of the haematopoietic system, including supporting megakaryocytic differentiation from CD34 + haematopoietic progenitor cells. Tumour necrosis factor alpha-induced protein 3 (TNFAIP3, also termed A20) plays a key role in terminating NF-jB signalling. Human genetic studies showed that the polymorphisms of the TNFAIP3 gene may contribute to ITP susceptibility. In this study, we showed a significant decrease in TNFAIP3 and increase in NF-jB/SMAD7 in ITP-MSCs. In co-cultures with CD34 + cells, NF-jB was overexpressed in MSCs from healthy controls (HC-MSCs) after transfection with NFKBIA (IjB)-specific short hairpin (sh)RNAs, resulting in MSC deficiency and a reduction in megakaryocytic differentiation and thrombopoiesis. Knockdown of TNFAIP3 expression using TNFAIP3-specific shRNAs in HC-MSCs affected megakaryocytopoiesis. However, IKBKB knockdown corrected megakaryocytopoiesis inhibition in the ITP-MSCs by decreasing NF-jB expression. Amplified TNFAIP3 expression in ITP-MSCs by TNFAIP3 cDNA can facilitate megakaryocyte differentiation. shRNAmediated knockdown of SMAD7 expression rescued the impaired MSC function in ITP patients. Therefore, we demonstrate that a pathological reduction in TNFAIP3 levels induced NF-jB/SMAD7 pathway activation, causing a deficiency in MSCs in ITP patients. The ability of ITP-MSCs to support megakaryocytic differentiation and thrombopoiesis of CD34 + cells was impaired.
Summary
Immune thrombocytopenia (ITP) is an autoimmune disease. Mesenchymal stem cells (MSCs) play important roles in the physiology and homeostasis of the haematopoietic system, including supporting megakaryocytic differentiation from CD34
+ haematopoietic progenitor cells. Tumour necrosis factor alpha-induced protein 3 (TNFAIP3, also termed A20) plays a key role in terminating NF-jB signalling. Human genetic studies showed that the polymorphisms of the TNFAIP3 gene may contribute to ITP susceptibility. In this study, we showed a significant decrease in TNFAIP3 and increase in NF-jB/SMAD7 in ITP-MSCs. In co-cultures with CD34 + cells, NF-jB was overexpressed in MSCs from healthy controls (HC-MSCs) after transfection with NFKBIA (IjB)-specific short hairpin (sh)RNAs, resulting in MSC deficiency and a reduction in megakaryocytic differentiation and thrombopoiesis. Knockdown of TNFAIP3 expression using TNFAIP3-specific shRNAs in HC-MSCs affected megakaryocytopoiesis. However, IKBKB knockdown corrected megakaryocytopoiesis inhibition in the ITP-MSCs by decreasing NF-jB expression. Amplified TNFAIP3 expression in ITP-MSCs by TNFAIP3 cDNA can facilitate megakaryocyte differentiation. shRNAmediated knockdown of SMAD7 expression rescued the impaired MSC function in ITP patients. Therefore, we demonstrate that a pathological reduction in TNFAIP3 levels induced NF-jB/SMAD7 pathway activation, causing a deficiency in MSCs in ITP patients. The ability of ITP-MSCs to support megakaryocytic differentiation and thrombopoiesis of CD34 + cells was impaired.
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Immune thrombocytopenia (ITP) is an autoimmune disease characterized by isolated thrombocytopenia (platelet count <100 9 10 9 /l) (Neunert et al, 2011; Ghanima et al, 2012; Rodeghiero & Ruggeri, 2014) . The pathogenesis of ITP mainly includes antibody-mediated platelet destruction and variably reduced platelet production. Problems at any stage of megakaryopoiesis can influence the production of platelets (Khodadi et al, 2016) . Megakaryopoiesis is a complex process that occurs in specific bone marrow niches and involves the complete differentiation of megakaryocyte (MK) progenitors into functional platelets. The specialized bone haematopoiesis microenvironment sustains MK maturation and platelet release into the circulation. MKs from ITP patients display abnormal maturation with normal or higher total counts. Human MKs commonly reach ploidy states of 8-128N, and polyploidy is required for functional MK maturation . ITP MKs may lack granularity, which is shown by reduced ploidy (Cines et al, 2014) . Bone marrow-derived mesenchymal stem cells (BM-MSCs) are key components in the haematopoietic microenvironment and provide support to haematopoiesis (Li & Wu, 2011) . A large number of studies have determined that MSCs are sufficient to support MK differentiation and platelet formation from CD34 + haematopoietic progenitor cells in vitro (Cheng et al, 2000) . MSCs secrete several cytokines that are related to proliferation and MK differentiation, including interleukin 6 (IL6), stem cell factor (SCF, also termed KITLG), granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GMCSF). MSCs can also directly interact with haematopoietic cells and MKs by expressing a number of adhesion molecules and integrins (Saleh et al, 2015) .
MSCs have adhesion properties and multilineage differentiation capacities; they can differentiate along the osteogenic, chondrogenic and adipogenic lineages. Many factors have been reported to influence MSC differentiation, such as NF-jB, TNFAIP3 (also termed A20), SMAD7, etc. The transcription factor NF-jB is critical for inflammatory signalling and innate and adaptive immunity. TNFAIP3, is a central regulator of immunopathology (Vereecke et al, 2009) , which plays a key role in terminating NF-jB signalling. SMAD7 is an important inhibitory factor in the transforming growth factor b/SMAD pathway. TGFb1 (TGFB1) is the most potent inhibitor of megakaryocytopoiesis (Greenberg et al, 1990; Kuter et al, 1992; Jackson et al, 1994; Caen et al, 1999) . NF-jB can suppress TGFb/ SMAD signalling by activating SMAD7 (Bitzer et al, 2000; Freudlsperger et al, 2013) . Activation of the NF-jB/SMAD7 pathway can lead to MSC differentiation deficiency . Dorronsoro et al (2013) demonstrated that the presence of TNFAIP3 allows MSCs to differentiate into adipocytes by maintaining NF-jB signalling at a basal level. Activated NF-jB inhibits osteogenic differentiation in bone marrow mesenchymal stem cells (Tang et al, 2013) . Zhou et al (2015) reported that polymorphisms in the TNFAIP3 gene may contribute to chronic ITP susceptibility. However, the relationship between the functions of MSCs and TNFAIP3, NF-jB and SMAD7 in ITP patients remains unknown.
Our previous study showed that MSCs from ITP patients displayed enhanced senescence and apoptosis and showed a lower capacity for inhibiting the proliferation of activated T cells, inducing regulatory T cells (Tregs) and suppressing the synthesis of anti-glycoprotein (GP)IIbIIIa antibodies. Thus, it was confirmed that BM-MSCs were defective in chronic ITP patients (Zhang et al, 2014b) .
Although BM-MSC dysfunction has been explored in ITP patients (Zhang et al, 2014b , it remains unclear whether TNFAIP3 plays a role in ITP-MSC dysfunction. Moreover, there is no available information on the influence of the ITP-MSC deficiency on megakaryocytopoiesis and thrombocytopoiesis. Thus, we aimed to investigate the role of TNFAIP3 in MSC dysfunction in ITP by specifically exploring whether MSC dysfunction influences megakaryocytopoiesis in ITP through the NF-jB/SMAD signalling pathway.
Methods

Patients and controls
Bone marrow samples were taken from the iliac crest of chronic ITP patients (n = 12; Table SI) and healthy subjects (n = 12) after informed consent had been obtained. Chronic ITP was defined as a platelet count <100 9 10 9 /l lasting for more than 12 months and having no other causes or disorders that could be associated with thrombocytopenia (Rodeghiero et al, 2009; Rodeghiero & Ruggeri, 2014) . Exclusion criteria included immune disorders, cancer, being aged less than 18 years old or older than 60 years old and a history of other diseases that are known to affect platelet count.
Isolation, expansion and co-culture of cells MSCs isolation. BM mononuclear cells were plated at a density of 10 7 cells/ml in media supplemented with 10% heat inactivated fetal bovine serum and 1% antibiotic-antimycotic, and incubated at 37°C in a 5% (vol/vol) humidified CO 2 chamber. The medium was exchanged after 48 h and every 3-4 days thereafter. When cultures reached 80% confluence, the cells were passaged and frozen for study. To confirm the human MSC phenotype, plastic adherent cells were analysed for the expression of surface-specific antigens using flow cytometry (Dominici et al, 2006) . The cells were stained with CD14, CD19, CD34, CD45, CD105, CD90 CD73 and HLA-DR fluorescein isothiocyanate (FITC)-conjugated, allophycocyanin (APC)-conjugated, peridinin chlorophyll protein (PerCP) -conjugated or phycoerythrin (PE)-conjugated monoclonal antibodies. The FITC-, PE-, APC-and PerCP-conjugated isotypes were used as negative controls. The analysis was performed using a flow cytometer (Beckman-Coulter Co, Hialeah, FL, USA). Once the third passage was reached, the MSCs were plated into 96-well tissue culture dishes in culture medium. Proliferation was assessed during each day of culture by measuring the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) dye absorbance of the cells at 570 nm.
Selection of CD34
+ bone marrow cells. Mononuclear cells were isolated from cord blood (CB) using Ficoll Hypaque density centrifugation (Centrifuge 5415D, Eppendorf, Westbury, NY, USA). The isolated cells were then washed and suspended in phosphate-buffered saline (PBS). CB CD34 + cells were purified by incubating the mononuclear cells with CD34-immunomagnetic bead cells. The CD34 + cells were collected by positive selection through a magnetic MACS MS cell separation column and then analysed by flow cytometry.
ATRA (All-trans retinoic acid) treatment. After removing the supernatant from the ITP-MSC cultures, the cells were detached using 0Á25% trypsin-EDTA at 37°C for 1 min. The cells were seeded in flasks at 1 9 10 6 cells/ml and treated with ATRA (50 lg/m) for 48 h. The total protein was extracted to detect TNFAIP3, NF-jB and SMAD7 levels using Western blotting.
Co-culture system -megakaryocytopoiesis assay
Vectors carrying either NFKBIA-or TNFAIP3-specific shRNAs were transduced into the MSCs from healthy controls (HC-MSCs). Vectors containing either IKBKB-specific shRNAs, TNFAIP3 cDNA or SMAD7-specific shRNAs were transduced into ITP-MSCs. The different MSCs were co-cultured with CD34 + cells separately for 12 days. The concentration of MSCs was 1 9 10 5 cells/ml, and the concentration of CD34 + cells was 3 9 10 5 cells/ml.
Flow cytometry. The cells collected from the cultures were washed twice with PBS, incubated with relevant antibodies, washed twice with PBS and analysed using a flow cytometer. For the commitment to MK lineage assay, the cells were harvested on day 7 and labelled with APCconjugated anti-CD41 and PE-conjugated anti-CD61. To determine the culture-derived platelet levels, CD34 + cellderived MKs were collected by centrifugation at 200g for 5 min, mixed with the supernatants and centrifuged a second time at 1550g for 10 min. The platelet-containing pellets were labelled with APC-CD41 and PE-CD42b antibodies in 100 ll PBS. After incubation at room temperature for 30 min in the dark, cell-associated immunofluorescence was analysed with a BD FACSCanto II flow cytometer (BD Biosciences, San Jose, CA, USA) (Chen et al, 2016) .
Ploidy analysis. CD34 + cell-derived MKs treated with NE or EPI were harvested and incubated with anti-CD41 for 20 min at 4°C. The cells were permeabilized with iced absolute methanol and then treated with a trypsin inhibitor/ RNase buffer. Finally, 10 mg/ml propidium iodide (PI) was added and incubated for 10 min. The cells expressing CD41 were gated and analysed with a BD FACSCanto II flow cytometer (BD Biosciences). RNA extraction and quantitative real-time polymerase chain reaction (qPCR) analysis
Colony-forming units (CFU
Total RNA was extracted from the cells using the TRIzol reagent (Invitrogen, Carlsbad, CA). RNA was transcribed into cDNA using the PrimeScript TM RT reagent kit (Takara, Dalian, China) according to the manufacturer's instructions. DNase-treated RNA (500 ng) was amplified with the gene-specific primers listed in Table I , using a one-step Power SYBR Green RNA-to-Ct kit (Applied Biosystems, Foster City, CA) on a LightCycler 480 II (Roche, Shanghai, China). The gene-specific primers are listed in Table I . A melting-curve analysis was performed to ensure specificity of the PCR products and all the PCR products were subjected to electrophoresis in an agarose gel to confine to a single band of the expected size. The expression of TNFAIP3, NF-jB and SMAD7 gene was normalized to RNA18S1 and determined using the comparative (2ÀDDCt) method.
Western blot analysis
The cells were washed twice with ice-cold PBS and extracted with lysis buffer (Sigma, St. Louis, MO, USA) for 45 min on ice. Equal amounts of protein were separated by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis and were electrophoretically transferred to polyvinylidene difluoride membranes. The membranes were then blocked with Tris-buffered saline with Tween (TBST) containing 5% non-fat dry milk for 1 h, and incubated overnight at 4°C with monoclonal antibodies (1:500-1,000 dilution) against SMAD4 (38454S, Cell Signaling Technology [CST], Danvers, MA< USA), SMAD2/3(CST, 8685S), phosphorylated (p)-SMAD2/3 (CST, 11979S), SMAD7 (ab190987, Abcam, Cambridge, UK), TNFAIP3 (CST, 5630S), p-RELA (also termed p-p65; CST, 3033S), and/or p-NFKBIA (also termed p-IjB; CST, 8242S). The Table I . Gene-specific primers used in this study.
Antisense 5 membranes were then washed with TBST and incubated with horseradish peroxidase-conjugated rabbit anti-mouse secondary antibody for 1 h. The blots were developed using an enhanced chemiluminescence kit. b-tubulin was used as an internal control for the cytoplasmic and nuclear proteins.
Gene silencing
ShRNA expression vectors were constructed using standard cloning procedures. The viral vector carrying shRNA sequences have been published previously and were purchased from Shanghai Genechem Co. Ltd (Shanghai, China; http://www.genechem.com.cn/Zaiti.aspx?zt=GV248). The shRNA sequences targeted the following proteins: (i) TNFA IP3i, ATTTCCAGTGTGTATCGGTGC; (ii) IKBKBi, ATGTT-CAAGATATGAACCAGC; (iii) NFKBIAi, AAGTGGAGTGGA GTCTGCTGC, and (iv) SMAD7i, TTCACAAAGCT-GATCTGCACG. MSC transduction was performed at a multiplicity of infection of four to achieve 50% infection and ten to achieve 100% infection.
Gene overexpression
TNFAIP3 was amplified from cDNA from purified T cells using the 5 0 -GAGGATCCCCGGGTACCGGTCGCCACCAT GGCTGAACAAGTCCTTCCTCAGGCTTTG -3 0 and 5 0 -TCC TTGTAGTCCATACCGCCATACATCTGCTTGAACTGAAAG CATTC -3 0 primer and cloned into the pcDNA3 vector to obtain pcDNA3-TNFAIP3 (http://www.genechem.com.cn/Za iti.aspx?zt=GV358). TNFAIP3 was then subcloned into the GV358 lentiviral vector.
Enzyme-linked immunosorbent assay (ELISA)
Cytokine [TNF-a, c-interferon (IFN-c), thrombopoietin (TPO), G-CSF, SCF, IL6, etc.] levels were assessed in MSC supernatant and peripheral blood (PB) plasma from ITP patients and health controls. All of the tests were processed with ELISA kits (R & D Systems, Minneapolis, MN, USA) according to the manufacturer's instructions.
Statistical analysis
The Gaussian distribution data are expressed as the mean AE standard deviations, while the skewness distribution data are expressed as a median (interquartile range). All of the data were analysed with the statistical software package SPSS version 13.0 (SPSS, Chicago, IL, USA). Statistical differences between two groups that conformed to the Gaussian distribution were analysed using the Student's t-test. The Mann-Whitney U Rank-sum test was used to analyse the data that did not conform to the Gaussian distribution. Statistical significance was defined as P < 0Á05.
Results
Mesenchymal stem cells are functionally abnormal in ITP patients
Immunophenotypic assays were performed after the third passaging, and there were no differences in immunophenotypes between the healthy control and ITP patients. Proliferating BM-MSCs normally express surface CD105, CD73 and CD90 markers at high levels but are negative for haematopoietic (CD45, CD14, CD11c and CD34) and HLA-DR markers.
MSCs morphology and growth assays. MSCs from the healthy controls and ITP patients both expanded and acquired spindle-shaped morphologies in culture; however, ITP-MSCs expanded more slowly. MTT proliferative assays were conducted on MSCs at days 1-7 after the third passage. The growth curves showed a lower proliferative capacity among ITP-MSCs compared with the MSC-control cells (Fig 1A) , which is similar to our previous study (Tang et al, 2013) .
Cytokine secretion by MSCs from ITP patients. Many cytokines influence megakaryocytopoiesis. Cytokines were detected in the supernatant of MSC cultures and serum from ITP patients and healthy controls using an ELISA. G-CSF was significantly higher expressed in ITP-MSCs when compared with HC-MSCs (447Á4 AE 121Á6 vs. 148Á7 AE 45Á38, P = 0Á0372). Moreover, the inflammation factors IFN-c (17Á76 AE 10Á16 vs. 46Á74 AE 8Á841, P = 0Á0493) and TNF-a (157Á9 AE 26Á77 vs. 444Á0 AE 99Á96, P = 0Á0152) also displayed higher expression in ITP-MSCs (Fig 2A) . There were no differences in TPO, GM-CSF, or IL6 expression in the MSCs from ITP patients or healthy controls. Additionally, the only cytokine that displayed expression differences in serum from ITP and healthy control patients was SDF-1a (P = 0Á0142) ( Fig 2B) .
MSCs growth assays in ITP patients. MSC 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) proliferative assays after the third passaging from ITP patients (mean AE SEM; n = 8) and healthy controls (mean AE SEM; n = 8) (*P < 0Á05).
The ability of ITP-MSCs to support megakaryocytic differentiation was impaired in CD34 + cells
MSCs from healthy controls and ITP patients were separately co-cultured with CD34 + cells. We compared the megakaryocytopoiesis-supportive activity of MSCs by estimating the relative cell counts (Sakurai et al, 2016) , MK ploidy and the culture-derived platelets in culture. The MK counts were analysed by examining the expression of CD41 and/or CD61 via flow cytometry. The relative number of MKs was the same between the healthy controls and ITP patients (10Á79 AE 0Á26% vs. 9Á98 AE 0Á1Á33%, P = 0Á564, Fig 3A, B) .and the of MK numbers were similar in the same two groups [the total number of CFU-MKs was 59Á94 AE 3Á002 (HC) vs. 60Á06 AE 2Á278 (ITP), P = 0Á4839; Fig 3C] . One of the most characteristic features of MK development is intranuclear mitosis, as the development of ploidy shows the maturity of the MK. Ploidy analysis on the MKs showed that the number of hyperploid MK cells (8N, 16N and ≥32N) in ITP-MSCs was significantly less than in HCMSCs (P < 0Á0001, P = 0Á0015 and P = 0Á0003, respectively, Fig 3E, F) . Thus, MSCs in ITP patients may play a role in abnormal MKs.
Flow cytometry analysis was used to examine CD41 and CD42b expression on day 12 of MK lineage culture in the different groups (Chen et al, 2016) . The relative number of culture-derived platelets in the ITP-MSCs was significantly lower than in HC-MSCs (5Á31 AE 0Á61% vs. 22Á43 AE 1Á19%, P < 0Á001; Fig 3G, H) . Thus, we demonstrated that ITPMSCs functioned abnormally, as their ability to support megakaryocytic differentiation into platelets was impaired in CD34 + cells.
Abnormal TNFAIP3/NF-jB/SMAD signalling in ITP patients
Many factors have been reported to influence MSC differentiation, including NF-jB, TNFAIP3 and SMAD7. To better understand the pathogenesis of the functions of abnormal ITP-MSCs, we examined the expression of TNFAIP3, NF-jB and TGF-b/SMAD in ITP-MSCs.
TNFAIP3 expression levels in MSCs from ITP patients. qPCR and Western blotting were performed to quantify TNFAIP3 expression in MSCs from ITP patients and healthy controls.
There was a significant decrease in TNFAIP3 expression in the ITP-MSCs compared with the HC-MSCs (Fig 4A, B ) (1Á255 AE 0Á867 vs. 0Á224 AE 0146, P = 0Á001).
NF-jB expression levels in MSCs from ITP patients. Considering that NF-jB activity can be modulated by the expression of the inhibitor protein IjB-a (also termed NFKBIA), we determined the mRNA levels of this gene in MSCs using qPCR. Relative NFKBIA mRNA expression levels were higher in MSCs from patients with ITP than in the healthy controls (1Á471 AE 0Á969 vs. 0Á837 AE 0Á336, P = 0Á063, Fig 4C) . Western blotting revealed that canonical NF-jB signalling was spontaneously activated in ITP-MSCs compared with HC-MSCs; this is shown by the increased phosphorylation and degradation of NFKBIA as well as decreased RELA (p65) phosphorylation (Fig 4D) .
SMAD7 over-expression attenuated the TGF-b signalling pathway. MSCs from ITP patients displayed upregulated expression of the inhibitory protein SMAD7 (5Á839 AE 0Á921 vs. 1Á269 AE 0Á202, P = 0Á0003, Fig 4E) and downregulation of p-SMAD2 [0Á078 (0Á196) vs. 1Á553 (0Á876), P < 0Á0001], p-SMAD3 [0Á027 (0Á217) vs. 1Á073 (1Á296), P < 0Á0001] and SMAD4 [0Á421 (0Á388) vs. 1Á909 (2Á718), P < 0Á0001]. These data demonstrated that SMAD7 was over-expressed and that this increased expression attenuated the TGF-b signalling pathway in MSCs from ITP patients (Fig 4F, G) .
Aberrant decreased TNFAIP3 expression activated the NF-jB/SMAD7 signalling pathway in ITP-MSCs
We investigated whether the reduced TNFAIP3 expression activated the NF-jB/SMAD7 signalling pathway and n = 8; *P < 0Á05) and healthy controls (mean AE SEM; n = 8; *P < 0Á05). G-CSF, granulocyte colony stimulating factor; M-CSF, macrophage colony stimulating factor; TPO, erythropoietin; b2-MG, b2 macroglobulin; GM-CSF, granulocyte macrophage colony stimulating factor; IFN-c, interferon-c; IL, interleukin; and TNF, tumour necrosis factor. attenuated the expression of TGF-b/SMAD. We used the TNFAIP3-specific shRNAs and TNFAIP3 cDNAs to change the expression of TNFAIP3 in HC-MSCs and ITP-MSCs, respectively, and then explored NF-jB and TGF-b/SMAD expression by Western blotting. The vectors carrying the TNFAIP3-specific shRNAs were transduced into MSCs from healthy donors. TNFAIP3 knockdown increased p-RELA, p-NFKBIA and SMAD7 expression and decreased p-SMAD2 and p-SMAD3 expression. These results indicated that TNFAIP3 knockdown by shRNA activates NF-jB signalling and suppresses TGF-b signalling in healthy MSCs (Fig 5A) . ITP-MSCs were transduced with vectors carrying TNFAIP3 cDNAs; this treatment rescued the aberrant NF-jB and SMAD signalling (Fig 5B) .
TNF-a contributed to the activation of NF-jB (Iwai, 2012) . MSCs from healthy donors were treated with TNF-a to activate the NF-jB signalling pathway. We observed that NF-jB signalling was activated after TNF-a treatment in HC-MSCs, which is similar to previous studies (Hymowitz & Wertz, 2010; Iwai, 2012; Wang et al, 2013; Catrysse et al, 2014) . Moreover, SMAD7 expression was also upregulated (Fig 5C) .
ATRA has been shown to inhibit NF-jB signalling (Rao et al, 2013; Hong et al, 2014; Zhang et al, 2014a) . MSCs from ITP patients were treated with ATRA, and TNFAIP3, NF-jB and SMAD expression was studied by Western blotting. The abnormal higher expression of NF-jB and SMAD7 were inhibited by ATRA treatment in ITP-MSCs t. In contrast, TNFAIP3 expression was rescued by ATRA treatment (Fig 5D) . Therefore, ATRA treatment could redress the abnormal TNFAIP3/NF-jB/SMAD7 signalling pathway. Thus, we demonstrated that the aberrantly lowered TNFAIP3 expression activated NF-jB/SMAD signalling in MSCs from ITP patients.
Abnormal TNFAIP3/NF-jB/SMAD signalling decreased megakaryocytopoiesis-supportive activities by MSCs in ITP patients
To determine how ITP-MSCs affect megakaryocytopoiesis via the TNFAIP3/NF-jB/SMAD7 pathway in humans, we studied the influence of this abnormal signalling pathway in a co-culture system. As mentioned above, there was significantly lower TNFAIP3 expression and higher NF-jB/SMAD7 expression in ITP-MSCs. Vectors carrying either IKBKB-specific shRNAs, TNFAIP3 cDNAs or SMAD7-specific shRNAs were transduced into ITP-MSCs to correct for the abnormal signalling. In the HC-MSCs, TNFAIP3 and NF-jB expression were knocked down by TNFAIP3-and NFKBIA-specific shRNAs, respectively. Then, MSCs with different treatments were co-cultured with CD34
+ cells separately, and we explored megakaryocytopoiesis in the co-culture system.
TNFAIP3 is a key regulator of megakaryocytopoiesis/ thrombocytopoiesis
HC-MSCs transfected with TNFAIP3-specific shRNAs. TN-FAIP3 expression was knocked down with TNFAIP3-specific shRNAs in HC-MSCs. HC-MSCs and HC-MSCs-TNFAIP3i were separately co-cultured with CD34 + cells, and MK and culture-derived platelet count were assessed as described above. The relative number of MKs was evaluated by flow cytometry analysis of CD41 and/or CD61. The relative number of MKs was the same in both HC-MSC and HC-MSCTNFAIP3i groups (8Á73 AE 0Á29% vs. 10Á18 AE 1Á36%, P = 0Á319, Fig 6A) . Ploidy analysis on the MKs from the different groups showed that the number of 2N MK cells in HC-MSCs-TNFAIP3i group, whose TNFAIP3 expression was knocked down, was significantly higher than in the HCMSCs (57Á63 AE 2Á14% vs. 49Á22 AE 1Á73%, P = 0Á008, Fig 6B) , although there was no difference between these two groups in the number of hyperploid MK cells (≥4N) (36Á26 AE 3% vs. 33Á24% AE 1Á09%, P = 0Á361, Fig 6B) . Flow cytometric analysis of CD41 and CD42b expression showed that the relative culture-derived platelet count was significantly lower in the HC-MSC-TNFAIP3i group than in the HC-MSC group (8Á60 AE 0Á42% vs. 22Á43 AE 1Á19%, P < 0Á001, Fig 6C, D) .
ITP-MSC transfection with TNFAIP3 cDNAs. Given the low TNFAIP3 expression in ITP-MSCs, TNFAIP3 expression in ITP-MSCs was amplified by treatment with TNFAIP3 cDNA. ITP-MSCs and ITP-MSC-TNFAIP3 cDNA were co-cultured with CD34 + cells separately, and megakaryocytopoieisis was studied in the co-culture system as described above. The relative number of MKs was evaluated by flow cytometric analysis of CD41 and/or CD61. The number of MKs was the same in the ITP-MSC and ITP-MSC-TNFAIP3 cDNA groups (8Á19 AE 0Á10% vs. 9Á98 AE 1Á33%, P = 0Á200, Fig 7A) . Ploidy analysis on the MKs from the different groups showed that there were significantly more number of 2N MK cells in the ITP-MSC group than in the ITP-MSC-TNFAIP3 cDNA group (50Á37 AE 1Á62% vs. 57Á63 AE 2Á14%, P = 0Á017, Fig 7B) . Moreover, there were significantly more hyperploid cells (≥4N) in MKs from the ITP-MSC-TNFAIP3 cDNA group than in the ITP-MSC group (39Á06 AE 1Á57% vs. 28Á56 AE 2Á14%, P = 0Á001, Fig 7B) . Flow cytometric analysis of CD41 and CD42b expression showed that the relative number of culture-derived platelets was significantly higher in the ITP-MSC-TNFAIP3 cDNA group than in the ITP-MSC group (24Á15 AE 1Á6% vs. 5Á31 AE 0Á61%, P < 0Á001, Fig 7C, D) . Thus, increasing TNFAIP3 expression in ITPMSCs with TNFAIP3 cDNAs corrected the deficiency caused by the ITP-MSCs.
Activated NF-jB signalling inhibits human megakaryocytopoiesis/thrombocytopoiesis in MSCs
Transfection of healthy control MSCs with NFKBIAshRNAs. Next, we wanted to see whether modulating the NF-jB pathway affects the supported ability of MSCs in megakaryocytosis. Lentiviral vectors carrying stable NFKBIA -specific shRNAs were used to transduce HC-MSCs to knock down NFKBIA. Knockdown of NFKBIA expression activated NF-jB signalling. HC-MSCs and HC-MSC-NFKBIAi were co-cultured with CD34 + cells separately. MK and culturederived platelet counts were assessed as described above. NFjB activation had no influence on the total relative number of MKs between the HC-MSC and HC-MSC-NFKBIAi groups (10Á79 AE 0Á26% vs. 10Á17 AE 0Á45%, P = 0Á0Á257, Fig 8A) . Ploidy analysis on the MKs in the co-culture system in the different groups showed that were significantly fewer 2N MK cells in HC-MSC-NFKBIAi group than in HC-MSC group (57Á65 AE 2Á14% vs. 51Á67 AE 1Á03%, P = 0Á025, Fig 8B) . In contrast, there were similar number of hyperploid cells (≥4N) in the HC-MSC-NFKBIAi group compared with the HC-MSC group (33Á24 AE 1Á09% vs. 34Á05 AE 2Á33%, P = 0Á759, Fig 8B) . The relative number of culture-derived platelets in the HC-MSC-NFKBIAi group, which displayed activated NF-jB expression, was significantly lower than in the healthy controls (17Á77 AE 0Á94% vs. 22Á43 AE 1Á19%, P = 0Á0085, Fig 8C, D) . Thus, we observed that NF-jB was overexpressed in HC-MSCs treated with NFKBIA-specific shRNAs, resulting in MSC deficiency that affected MK differentiation.
ITP-MSCs transfection with IKBKB-shRNA. The NF-jB signalling pathway was activated in the ITP-MSCs similarly to the above described experiment. We used transduced ITPMSCs with vectors carrying stable IKBKB-specific shRNAs to silence NF-jB signalling. ITP-MSCs and ITP-MSC-IKBKBi were co-cultured with CD34 + cells separately, and megakaryocytopoiesis was analysed in the co-culture system. The relative number of MKs was the same in both the ITP-MSC and ITP-MSC-IKBKBi groups (9Á98 AE 1Á33% vs. 8Á50 AE 0Á58%, P = 0Á325, Fig 9A) . Ploidy analysis on the MKs showed that there were significantly fewer hypoploid MKs (2N) in the ITP-MSC-IKBKBi group compared with the ITP-MSC group (57Á18 AE 1Á53% vs. 50Á57 AE 1Á79%, P = 0Á014, Fig 9B) . Moreover, there were significantly more hyperploid cells (≥4N) in the ITP-MSC-IKBKBi group than the ITP-MSC group (38Á00 AE 1Á96% vs. 28Á56 AE 2Á14%, P = 0Á005, Fig 9B) . The relative culture-derived platelet count was significantly higher in the ITP-MSC-IKBKBi group than in ITPMSCs (14Á70 AE 0Á84% vs. 5Á31 AE 0Á61%, P < 0Á001, Fig 9C,  D) . Thus, we observed that when extreme activation of NFjB signalling is silenced by IKBKB-shRNAs, the abnormal MSC function that supports megakaryocytopoiesis was rescued.
Higher SMAD7 expression induced lower megakaryocytopoiesis/thrombocytopoiesis SMAD7 expression was high in ITP-MSCs; thus ITP-MSCs were transduced with lentiviral vectors carrying stable SMAD7-specific shRNAs. ITP-MSCs and ITP-MSC-SMAD7i were co-cultured with CD34 + cells separately. MK and culture-derived platelet counts were assessed as previously described above. There were no differences in the number of MKs between the ITP-MSC and ITP-MSC-SMAD7i groups (9Á98 AE 1Á33% vs. 9Á68 AE 1Á25%, P = 0Á869 Fig 10A) . The number of hypoploid MKs (2N) in the ITP-MSC group was significantly higher than in the ITP-MSC-SMAD7i group (42Á7 AE 0Á41% vs. 57Á18 AE 1Á53%, P < 0Á001, Fig 10B) . Moreover, there were significantly more hyperploid cells (≥4N) in the ITP-MSC-SMAD7i groups than in the ITP-MSC group (44Á62 AE 0Á33% vs. 28Á56 AE 2Á14%, P < 0Á001, Fig 10B) . Flow cytometry analysis showed that the relative number of culture-derived platelets in the ITP-MSC-SMAD7i group was significantly higher than the ITP-MSC group (18Á85 AE 1Á66% vs. 5Á31 AE 0Á61%, P < 0Á001, Fig 10C, D) . Therefore, SMAD7 knockdown rescued the deficiency associated with ITPMSCs.
ATRA may improve ITP-MSC megakaryocytopoiesissupportive activities
ATRA treatment could redress the abnormal TNFAIP3/NFjB/SMAD7 signalling pathway in ITP-MSCs. ITP-MSCs were treated with ATRA and then co-cultured with CD34 + cells.
The relative number of MKs was similar between the two groups (8Á41 AE 0Á5% vs. 9Á98 AE 1Á33%, P = 0Á288, Fig 11A) . Ploidy analysis showed that there were significantly fewer hypoploid MKs in the ITP-MSCs-ATRA group than in the ITP-MSC group (44Á02 AE 0Á39% vs. 57Á18 AE 1Á53%, P < 0Á001, Fig 11B) . Moreover, there were significantly more hyperploid cells (≥4N) in the ITP-MSC-ATRA group than in the ITP-MSC group (43Á21 AE 0Á53% vs. 28Á56 AE 2Á14%, P < 0Á001, Fig 11B) . The relative number of culture-derived platelets was significantly higher in the ITP-MSC-ATRA group than in the ITP-MSC group (19Á86 AE 1Á09% vs. 5Á31 AE 0Á61%, P < 0Á001, Fig 11C, D) . Thus, ATRA improved the megakaryocytopoiesis-supportive abilities of the ITP-MSCs when they were co-cultured with CD34 + cells in vitro.
Proposed model for abnormal signalling pathway in ITP patients. TNF-a activates NF-jB signalling through the sequential regulation of IKBKB kinases, leading to phosphorylation of NFKBIA, nuclear translocation and phosphorylation of the NF-jB subunit RELA and activation of downstream targets in ITP-MSCs. TNFAIP3 is a negative feedback regulator of NF-jB signalling. Reduced TNFAIP3 expression activates NF-jB signalling, which therefore increases SMAD7 expression and attenuates the TGF-b signalling pathway (Fig 12) .
Discussion
In this study, we demonstrated that aberrantly decreased TNFAIP3 expression induced MSC impairments in ITP via the NF-jB/SMAD pathway; the associated MSC dysfunction influences megakaryocytopoiesis in ITP. Megakaryopoiesis is a complex process that occurs in specific bone marrow niches that involves the complete differentiation of MK progenitors into functional platelets. MKs from ITP patients displayed abnormal maturation with normal or higher total counts. Human MKs commonly reach ploidy states of 8-128N, and polyploidy is required for functional human MK maturation . Our study investigated the abnormal decreased TNFAIP3 expression that induced the activation of the NF-jB/SMAD7pathway, leading to dysfunctional MSCs that are unable to support ploidy development and platelet formation in ITP. TNFAIP3, the product of the TNFAIP3 gene, was first identified in endothelial cells as a primary response gene induced upon treatment with TNF (Dixit et al, 1990) . TNFAIP3 is an ubiquitin-editing protein with dual functions including a deubiquitinating enzyme (DUB) activity mediated by its N-terminal ovarian tumour (OTU) domain and an E3 ubiquitin ligase activity mediated by its C-terminal zinc finger-containing domain (Wertz et al, 2004; Catrysse et al, 2014) . In most cell types, basal TNFAIP3 expression is very low (Coornaert et al, 2009) ; upon its expression, TNFAIP3 functions as a negative feedback regulator of NF-jB activation (Vereecke et al, 2009; Catrysse et al, 2014) and as a central regulator of immunopathology.
TNFAIP3 is a susceptibility locus for inflammatory and autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, etc. A number of researchers have focused on the role of TNFAIP3 in different cell types with TNFAIP3-knockout or -knockdown rats, which have shown that TNFAIP3 may have very different functions in different cell types. It has been reported that TNFAIP3 deficiency in the haematopoietic system causes thrombocytopenia (Nagamachi et al, 2014; Nakagawa et al, 2015) . Zhou et al (2015) observed significant differences in the allelic and genotypic distributions of TNFAIP3 (rs2230926 and rs5029939) between ITP and control groups, indicating that polymorphisms in the TNFAIP3 gene may contribute to chronic ITP susceptibility. The present study, illuminated the effects of significantly lower TNFAIP3 expression and significant NF-jB activation in MSCs from patients with ITP.
Reducing TNFAIP3 expression may sensitize cells to the development of inflammatory pathology and systemic autoimmunity by activating NF-jB signalling. The NF-jB family of transcription factors comprises five related proteins, REL (c-Rel), RELA (p65), RELB, NFKB1 (p50) and NFKB2 (p52), that interact to form homodimers and heterodimers with distinct gene regulatory functions. In most cells, NF-jB dimers are inactive in the cytosol; they are retained in a latent state via interactions with NFKBIA proteins (Gilmore, 2006) . The overall NF-jB pathway is divided into two distinct but interacting halves, the classical (also known as canonical) and the alternate (non-canonical) NF-jB pathways. In the present study, we focused on the classical NFjB pathways. Immune signals that include antigens, Toll-like receptor (TLR) ligands and inflammatory cytokines, such TNF and IL1b (IL1B), lead to the phosphorylation-dependent activation of IKBKB, which in turn phosphorylates NFKBIAassociated with NF-jB dimers, triggering its polyubiquitination and subsequent proteasome-mediated degradation (Gilmore, 2006; Gerondakis et al, 2014) .
NF-jB can be activated in virtually every cell type. The NF-jB signal transduction pathway is best known as a major regulator of innate and adaptive immune responses. The majority of studies have reported that the NF-jB signalling pathway may contribute to autoimmune diseases including rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosus, as well as inflammatory bowel diseases and psoriasis (Dale et al, 2006) . NF-jB controls T cell development (Gerondakis et al, 2014) , and NF-jB signalling is associated with T cell tolerance in ITP (Ji et al, 2014) . Some articles have reported the role of NF-jB in MSC Proposed model for aberrantly decreased TNFAIP3 expression as well as the activation of the NF-jB/SMAD7 pathway and attenuation of the canonical TGF-b/SMAD signalling pathway in ITP patients. TNF-a activates NF-jB signalling through a sequential regulation of IKBKB kinases leading to phosphorylation of NFKBIA, nuclear translocation and phosphorylation of the NF-jB subunit RELA and activation of downstream targets in ITP-MSCs. TNFAIP3 is a negative feedback regulator of NF-jB signalling. Reduced TNFAIP3 expression activates NF-jB signalling, which therefore increases SMAD7 expression and attenuates the TGF-b signalling pathway. differentiation , which provided some ideas for this study. In this study, we showed that activated NF-jB signalling in ITP patients and abnormal NF-jB signalling influence MK differentiation and thrombocytopoiesis by affecting MSCs.
It has been reported that there is a cross-talk between the TGF-b and NF-jB pathways (Bitzer et al, 2000; Freudlsperger et al, 2013) .The TGF-b signalling pathway regulates a wide array of cellular processes, such as apoptosis, proliferation and differentiation, with TGFb ligands conveying intracellular signals through the SMAD signalling pathway. SMAD proteins can be divided into the 3 functional classes depending on their role in the pathway: (i) receptor-activated SMADs (R-SMAD; SMAD1, 2, 3, 5 and 8), (ii) common mediator SMADs (CO-SMAD; SMAD4) and (iii) inhibitory SMADs (I-SMAD; SMAD6 and SMAD7) (Derynck & Zhang, 2003; Yan et al, 2009) . Ligand binding followed by receptor phosphorylation activates intracellular R-SMADs, which then form a complex with SMAD4. The activated complex subsequently translocates into the nucleus where it regulates target gene transcription. SMAD7 is an important inhibitory factor in the TGF-b/SMAD pathway, which is one of the important signalling pathways that regulate MK differentiation (Emmrich et al, 2014) . NFjB/SMAD7 pathway activation led to deficiencies in MSC differentiation . In this article, we demonstrated that activated SMAD7 expression and attenuated TGFbeta signalling (Bao et al, 2010) , including via SMAD2 and SMAD3, influenced the ability of MSCs in ITP patients. Some researchers have reported a relationship between NF-jB/ SMAD7 signalling and the osteogenic differentiation capabilities of MSCs. TGFb1 is the most potent inhibitor of megakaryocytopoiesis (Greenberg et al, 1990; Kuter et al, 1992; Jackson et al, 1994; Caen et al, 1999) . Here, we explored how aberrant lower TNFAIP3 expression induced activated NF-jB/SMAD7 signalling in ITP-MSCs.
MSCs play an important role in the physiology and homeostasis of the haematopoietic system. This is because MSCs generate most of the stromal cells present in the bone marrow (BM) and form part of the haematopoietic stem cell niche. The haematopoiesis-supporting capacities of MSCs have been demonstrated previously (FajardoOrduna et al, 2015) . Cell-cell interactions and cytokine secretion simultaneously contribute to differentiation in terminal MK lineage cells as well as platelet production within the BM niche. MSCs express and secrete a wide range of cytokines and soluble factors, including IL6, IL11, SCF and leukaemia inhibitory factor (LIF), which are important stimulators of MK biogenesis and maturation. In addition to cytokine secretion, MSCs can directly interact with haematopoietic cells and MKs through the expression of adhesion molecules, such as intercellular adhesion molecules 1 and 2, vascular cell adhesion molecule 1, and E-selectin. MSCs are sufficient to support megakaryocytopoiesis and platelet formation from CD34 + haematopoietic progenitor cells in vitro (Cheng et al, 2000; Angelopoulou et al, 2003) . Our previous study demonstrated that MSCs from ITP patients displayed enhanced senescence and apoptosis and showed a lower capacity for inhibiting the proliferation of activated T cells by inducing Tregs and suppressing the synthesis of anti-GPIIb-IIIa antibodies . Additional studies have confirmed the defective BM-MSCs in chronic ITP patients (Zhang et al, 2014b) . In this study, we found that MSCs can support MK formation from CD34 + haematopoietic progenitor cells, which was also observed in a previous report (Cheng et al, 2000) . We also demonstrated that MSCs were defective in supporting megakaryocytopoiesis of CD34 + cells in patients with ITP.
ATRA and other retinoids have been recognized as chemopreventive and chemotherapeutic agents in cancer prevention and treatment, including in acute promyelocytic leukaemia and squamous cell carcinoma. ATRA has also been reported as an anti-inflammation agent in clinical trials for human inflammatory diseases, such as emphysema. ATRA inhibited NF-jB signalling and ATRA therapy could induce significant changes in Tregs cells to induce responses in patients with chronic ITP (Dai et al, 2016) . The present study demonstrated that ATRA treatment inhibited the abnormally high NF-jB and SMAD7 expression in MSCs from ITP patients. Moreover, TNFAIP3 expression was rescued by ATRA treatment. Thus, we demonstrated that ATRA treatment could redress the abnormal TNFAIP3/NF-jB/ SMAD 7 signalling pathway.
In conclusion, we demonstrated for the first time that a pathological reduction in TNFAIP3 levels induced NF-jB/ SMAD7 pathway activation, which led to a deficiency in MSCs from patients with ITP. The ability of ITP-MSCs to support megakaryocytic differentiation and thrombopoiesis of CD34 + cells was impaired. Therefore, aberrant TNFAIP3/NF-jB/ SMAD pathway signalling may cause ITP pathogenesis and this study indicates that TNFAIP3 regulation could be a potential therapeutic strategy against NF-jB signalling in ITP. and X.-l.Z. performed experiments, analysed the results; H.-x.F evaluated the data. L.-p.X., K.-y.L. reviewed the paper.
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